Moderna has initiated a human trial for a vaccine targeting Bundibugyo ebolavirus. This strain of Ebola has resulted in a significant number of deaths. The trial is the company's first involving human participants for this specific vaccine.

Moderna announced the start of the trial, marking a step forward in efforts to develop protection against Bundibugyo ebolavirus. Further information on the trial, including details about its progress and participants, can be found through Reuters or other news sources, such as the Galveston County Daily News.